Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Seeking the optimal aspirin dose in acute coronary syndromes.

× No keyword cloud information.

9 in total

1. Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome.

Authors: Ian M Kronish; Nina Rieckmann; Daichi Shimbo; Matthew Burg; Karina W Davidson
Journal: Am J Cardiol Date: 2010-10-15 Impact factor: 2.778

Review 2. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

Authors: Timothy D Warner; Sven Nylander; Carl Whatling
Journal: Br J Clin Pharmacol Date: 2011-10 Impact factor: 4.335

3. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.

Authors: L Kristin Newby; Manjushri V Bhapkar; Harvey D White; David J Moliterno; Nancy M Allen LaPointe; David E Kandzari; Freek W A Verheugt; Judith M Kramer; Paul W Armstrong; Robert M Califf
Journal: J Thromb Thrombolysis Date: 2003-12 Impact factor: 2.300

Review 4. The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.

Authors: Abigail Johnston; W Schuyler Jones; Adrian F Hernandez
Journal: Curr Cardiol Rep Date: 2016-08 Impact factor: 2.931

5. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.

Authors: Chiara Cerletti; Giuseppe Dell'Elba; Stefano Manarini; Romina Pecce; Augusto Di Castelnuovo; Nicola Scorpiglione; Vincenzo Feliziani; Giovanni de Gaetano
Journal: Clin Pharmacokinet Date: 2003 Impact factor: 6.447

6. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study.

Authors: Jeffrey S Berger; David L Brown; Gregory L Burke; Albert Oberman; John B Kostis; Robert D Langer; Nathan D Wong; Sylvia Wassertheil-Smoller
Journal: Circ Cardiovasc Qual Outcomes Date: 2009-03-05

Seeking the optimal aspirin dose in acute coronary syndromes.

1. Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome.

Review 2. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

3. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.

Review 4. The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.

5. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.

6. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study.

7. How can clinical researchers quantify the value of their proposed comparative research?

8. COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood.

Review 9. Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.